Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages


This content is available also in other languages

November 17, 2009 | Corporate News | English

Tecan announces global OEM agreement to supply fully automated solution for Hologic Cervista® molecular diagnostics HPV tests

  • Prototypes have already been successfully tested
  • The U.S. market launch of automated Cervista systems is expected in 2010

Männedorf, Switzerland, November 16, 2009 – The Tecan Group (SIX Swiss Exchange: TECN) today announced a global OEM agreement with Hologic, Inc., (NASDAQ: HOLX), the women's healthcare company. Under the agreement, Tecan will supply a fully automated solution for Hologic’s Cervista® molecular diagnostics human papillomavirus (HPV) tests. The system is based on Tecan’s flexible and reliable Freedom EVO® liquid handling platform with an integrated Tecan detection device. Prototypes of the automated solution have already been successfully tested with select Hologic customers.. Validation units to be used to generate the necessary data for regulatory approval of the automated system in the U.S. will be supplied before the end of 2009. Tecan expects to ship commercial quantities for Hologic starting in 2010. Tecan will also
supply Hologic with plastic consumables as an integral part of the validated system. Financial details were not disclosed.

About Human Papillomavirus and Cervical Cancer
HPV is the most common sexually transmitted disease in the United States and is recognized as the cause of most cervical cancers. To help prevent the onset of disease, the American College of Obstetrics and Gynecology (ACOG) suggests routine Pap and HPV testing for women over the age of 30 to identify women most likely to develop cervical cancer.

About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health.

Hologic, Cervista, are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries
in the United States and/or other countries.


About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions for the biopharma, forensic and diagnostic industries. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. With its subsidiary REMP (www.remp.com), Tecan is the market leader in automated laboratory storage and logistics systems. Its clients include pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2008, Tecan generated sales of CHF 396 million (USD 366.7 million; EUR 250.7 million). Registered shares of Tecan Group are traded on the SWX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019). TECZn.S / Valor: 1210019).




For further information please contact:

Tecan Group Ltd.
Martin Braendle
Head of Corporate Communications &
Investor Relations

T +41 (0) 44 922 84 30
F +41 (0) 44 922 88 89